Malignant epithelial tumor of salivary glands

Malignant epithelial tumors of the salivary glands are a heterogeneous group of rare cancers that arise from the epithelial cells lining the salivary glands. These tumors can develop in the major salivary glands — including the parotid gland (the most common site), the submandibular gland, and the sublingual gland — as well as in the minor salivary glands distributed throughout the oral cavity, pharynx, and upper aerodigestive tract. This category encompasses several distinct histological subtypes, including mucoepidermoid carcinoma, adenoid cystic carcinoma, acinic cell carcinoma, salivary duct carcinoma, adenocarcinoma not otherwise specified, and other rarer variants. Each subtype has different biological behavior, prognosis, and clinical characteristics. Patients typically present with a painless or slowly growing mass in the affected salivary gland region. Depending on the tumor's location and aggressiveness, symptoms may include facial pain, facial nerve paralysis (particularly with parotid tumors), difficulty swallowing, numbness, or fixation of the mass to surrounding tissues. More aggressive subtypes may metastasize to regional lymph nodes, lungs, bone, or liver. The disease primarily affects the head and neck region but can have systemic consequences when metastatic spread occurs. Treatment typically involves surgical resection as the primary modality, often followed by adjuvant radiation therapy, particularly for high-grade tumors, advanced-stage disease, close or positive surgical margins, or perineural invasion. Chemotherapy may be considered for recurrent or metastatic disease, though salivary gland carcinomas are generally less chemosensitive than other head and neck cancers. Emerging targeted therapies, including androgen receptor-directed therapy for salivary duct carcinoma and therapies targeting specific molecular alterations (such as NTRK fusions), are expanding the treatment landscape. Prognosis varies widely depending on histological subtype, tumor grade, stage at diagnosis, and completeness of surgical resection.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Malignant epithelial tumor of salivary glands